27 results on '"Viggiani, Pietro"'
Number of results to display per page
Search Results
2. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres
- Author
-
Riccardi, Niccolò, Alagna, Riccardo, Saderi, Laura, Ferrarese, Maurizio, Castellotti, Paola, Mazzola, Ester, De Lorenzo, Saverio, Viggiani, Pietro, Udwadia, Zarir, Besozzi, Giorgio, Cirillo, Daniela, Sotgiu, Giovanni, Codecasa, Luigi, and for StopTB Italia Onlus Group
- Published
- 2019
- Full Text
- View/download PDF
3. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
- Author
-
Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, Migliori, Giovanni Battista, Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista
- Published
- 2021
4. Multicenter evaluation of xpert MTB/RIF ultra tests reporting detection of “Trace” of Mycobacterium tuberculosis DNA
- Author
-
Tortoli, Enrico, primary, Mazzola, Ester, additional, Monte, PaolaDal, additional, Piersimoni, Claudio, additional, Giudice, AnnalisaDel, additional, Camaggi, Anna, additional, Pedrotti, Cristina, additional, Gurrieri, Francesca, additional, Russo, Cristina, additional, Farina, Claudio, additional, Lombardi, Alessandra, additional, Viggiani, Pietro, additional, Cenci, Elio, additional, Nisticò, Salvatore, additional, Rognoni, Vanina, additional, Sala, Eugenio, additional, Cichero, Paola, additional, Frizzera, Eliana, additional, Monzillo, Vincenzina, additional, Morini, Fulvia, additional, Scarparo, Claudio, additional, Borroni, Emanuele, additional, and Cirillo, DanielaM, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
- Author
-
Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan-Willem, Al-Marzouqi, Nada Hassan, Arias-Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey E., Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García-García, José-María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska-Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado-Laborín, Rafael, Li, Yang, Magis-Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Munoz-Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie-Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Skrahina, Alena, Šmite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, and Zignol, Matteo
- Published
- 2019
- Full Text
- View/download PDF
6. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
- Author
-
Borisov, Sergey, primary, Danila, Edvardas, additional, Maryandyshev, Andrei, additional, Dalcolmo, Margareth, additional, Miliauskas, Skaidrius, additional, Kuksa, Liga, additional, Manga, Selene, additional, Skrahina, Alena, additional, Diktanas, Saulius, additional, Codecasa, Luigi Ruffo, additional, Aleksa, Alena, additional, Bruchfeld, Judith, additional, Koleva, Antoniya, additional, Piubello, Alberto, additional, Udwadia, Zarir Farokh, additional, Akkerman, Onno W., additional, Belilovski, Evgeny, additional, Bernal, Enrique, additional, Boeree, Martin J., additional, Cadiñanos Loidi, Julen, additional, Cai, Qingshan, additional, Cebrian Gallardo, Jose Joaquín, additional, Dara, Masoud, additional, Davidavičienė, Edita, additional, Forsman, Lina Davies, additional, De Los Rios, Jorge, additional, Denholm, Justin, additional, Drakšienė, Jacinta, additional, Duarte, Raquel, additional, Elamin, Seifeldin Eltaeb, additional, Escobar Salinas, Nadia, additional, Ferrarese, Maurizio, additional, Filippov, Alexey, additional, Garcia, Ana, additional, García-García, José-María, additional, Gaudiesiute, Ieva, additional, Gavazova, Blagovesta, additional, Gayoso, Regina, additional, Gomez Rosso, Roscio, additional, Gruslys, Vygantas, additional, Gualano, Gina, additional, Hoefsloot, Wouter, additional, Jonsson, Jerker, additional, Khimova, Elena, additional, Kunst, Heinke, additional, Laniado-Laborín, Rafael, additional, Li, Yang, additional, Magis-Escurra, Cecile, additional, Manfrin, Vinicio, additional, Marchese, Valentina, additional, Martínez Robles, Elena, additional, Matteelli, Alberto, additional, Mazza-Stalder, Jesica, additional, Moschos, Charalampos, additional, Muñoz-Torrico, Marcela, additional, Mustafa Hamdan, Hamdan, additional, Nakčerienė, Birutė, additional, Nicod, Laurent, additional, Nieto Marcos, Magnolia, additional, Palmero, Domingo Juan, additional, Palmieri, Fabrizio, additional, Papavasileiou, Apostolos, additional, Payen, Marie-Christine, additional, Pontarelli, Agostina, additional, Quirós, Sarai, additional, Rendon, Adrian, additional, Saderi, Laura, additional, Šmite, Agnese, additional, Solovic, Ivan, additional, Souleymane, Mahamadou Bassirou, additional, Tadolini, Marina, additional, van den Boom, Martin, additional, Vescovo, Marisa, additional, Viggiani, Pietro, additional, Yedilbayev, Askar, additional, Zablockis, Rolandas, additional, Zhurkin, Dmitry, additional, Zignol, Matteo, additional, Visca, Dina, additional, Spanevello, Antonio, additional, Caminero, José A., additional, Alffenaar, Jan-Willem, additional, Tiberi, Simon, additional, Centis, Rosella, additional, D'Ambrosio, Lia, additional, Pontali, Emanuele, additional, Sotgiu, Giovanni, additional, and Migliori, Giovanni Battista, additional
- Published
- 2019
- Full Text
- View/download PDF
7. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery
- Author
-
Borisov, Sergey E., primary, D'Ambrosio, Lia, additional, Centis, Rosella, additional, Tiberi, Simon, additional, Dheda, Keertan, additional, Alffenaar, Jan-Willem, additional, Amale, Rohit, additional, Belilowski, Evgeny, additional, Bruchfeld, Judith, additional, Canneto, Barbara, additional, Denholm, Justin, additional, Duarte, Raquel, additional, Esmail, Aliasgar, additional, Filippov, Alex, additional, Davies Forsman, Lina, additional, Gaga, Mina, additional, Ganatra, Shashank, additional, Igorevna, Gaida Anastasia, additional, Lazaro Mastrapa, Barbara, additional, Manfrin, Vinicio, additional, Manga, Selene, additional, Maryandyshev, Andrey, additional, Massard, Gilbert, additional, González Montaner, Pablo, additional, Mullerpattan, Jai, additional, Palmero, Domingo Juan, additional, Pontarelli, Agostina, additional, Papavasileiou, Apostolos, additional, Pontali, Emanuele, additional, Romero Leyet, Rodolfo, additional, Spanevello, Antonio, additional, Udwadia, Zarir Farokh, additional, Viggiani, Pietro, additional, Visca, Dina, additional, Sotgiu, Giovanni, additional, and Migliori, Giovanni Battista, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery
- Author
-
Borisov, Sergey E., primary, D’ambrosio, Lia, additional, Centis, Rosella, additional, Dheda, Keertan, additional, Alffenaar, Jan-Willem, additional, Amale, Rohit, additional, Belilowski, Evgeny, additional, Bruchfeld, Judith, additional, Canneto, Barbara, additional, Denholm, Justin, additional, Duarte, Raquel, additional, Esmail, Aliasgar, additional, Filippov, Alex, additional, Davies Forsman, Lina, additional, Gaga, Mina, additional, Ganatra, Shashank, additional, Igorevna, Gaida Anastasia, additional, Lazaro Mastrapa, Barbara, additional, Manfrin, Vinicio, additional, Manga, Selene, additional, Maryandyshev, Andrey, additional, Massard, Gilbert, additional, González Montaner, Pablo, additional, Mullerpattan, Jai, additional, Palmero, Domingo Juan, additional, Pontarelli, Agostina, additional, Papavasileiou, Apostolos, additional, Pontali, Emanuele, additional, Romero Leyet, Rodolfo, additional, Spanevello, Antonio, additional, Tiberi, Simon, additional, Tramontana, Adrian, additional, Udwadia, Zarir Farokh, additional, Viggiani, Pietro, additional, Visca, Dina, additional, Sotgiu, Giovanni, additional, and Migliori, Giovanni Battista, additional
- Published
- 2018
- Full Text
- View/download PDF
9. Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results
- Author
-
Borisov, Sergey E., primary, Dheda, Keertan, additional, Enwerem, Martin, additional, Romero Leyet, Rodolfo, additional, D’Ambrosio, Lia, additional, Centis, Rosella, additional, Sotgiu, Giovanni, additional, Tiberi, Simon, additional, Alffenaar, Jan-Willem, additional, Maryandyshev, Andrey, additional, Belilowski, Evgeny, additional, Ganatra, Shashank, additional, Skrahina, Alena, additional, Akkerman, Onno, additional, Aleksa, Alena, additional, Amale, Rohit, additional, Artsukevich, Janina, additional, Bruchfeld, Judith, additional, Caminero, Jose A., additional, Carpena Martinez, Isabel, additional, Codecasa, Luigi, additional, Dalcolmo, Margareth, additional, Denholm, Justin, additional, Douglas, Paul, additional, Duarte, Raquel, additional, Esmail, Aliasgar, additional, Fadul, Mohammed, additional, Filippov, Alex, additional, Davies Forsman, Lina, additional, Gaga, Mina, additional, Garcia-Fuertes, Julia- Amaranta, additional, Garcia-Garcia, Jose Maria, additional, Gualano, Gina, additional, Jonsson, Jerker, additional, Kunst, Heinke, additional, Lau, Jillian S., additional, Lazaro Mastrapa, Barbara, additional, Lazaro Teran Troya, Jorge, additional, Manga, Selene, additional, Manika, Katerina, additional, González Montaner, Pablo, additional, Mullerpattan, Jai, additional, Oelofse, Suzette, additional, Ortelli, Martina, additional, Palmero, Domingo Juan, additional, Palmieri, Fabrizio, additional, Papalia, Antonella, additional, Papavasileiou, Apostolos, additional, Payen, Marie-Christine, additional, Pontali, Emanuele, additional, Robalo Cordeiro, Carlos, additional, Sadutshang, Tsetan Dorji, additional, Sanukevich, Tatsiana, additional, Solodovnikova, Varvara, additional, Spanevello, Antonio, additional, Topgyal, Sonam, additional, Toscanini, Federica, additional, Tramontana, Adrian, additional, Udwadia, Zarir Farokh, additional, Viggiani, Pietro, additional, White, Veronica, additional, Zumla, Alimuddin, additional, and Migliori, Giovanni Battista, additional
- Published
- 2017
- Full Text
- View/download PDF
10. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study
- Author
-
Borisov, Sergey E., primary, Dheda, Keertan, additional, Enwerem, Martin, additional, Romero Leyet, Rodolfo, additional, D'Ambrosio, Lia, additional, Centis, Rosella, additional, Sotgiu, Giovanni, additional, Tiberi, Simon, additional, Alffenaar, Jan-Willem, additional, Maryandyshev, Andrey, additional, Belilovski, Evgeny, additional, Ganatra, Shashank, additional, Skrahina, Alena, additional, Akkerman, Onno, additional, Aleksa, Alena, additional, Amale, Rohit, additional, Artsukevich, Janina, additional, Bruchfeld, Judith, additional, Caminero, Jose A., additional, Carpena Martinez, Isabel, additional, Codecasa, Luigi, additional, Dalcolmo, Margareth, additional, Denholm, Justin, additional, Douglas, Paul, additional, Duarte, Raquel, additional, Esmail, Aliasgar, additional, Fadul, Mohammed, additional, Filippov, Alexey, additional, Davies Forsman, Lina, additional, Gaga, Mina, additional, Garcia-Fuertes, Julia-Amaranta, additional, García-García, José-María, additional, Gualano, Gina, additional, Jonsson, Jerker, additional, Kunst, Heinke, additional, Lau, Jillian S., additional, Lazaro Mastrapa, Barbara, additional, Teran Troya, Jorge Lazaro, additional, Manga, Selene, additional, Manika, Katerina, additional, González Montaner, Pablo, additional, Mullerpattan, Jai, additional, Oelofse, Suzette, additional, Ortelli, Martina, additional, Palmero, Domingo Juan, additional, Palmieri, Fabrizio, additional, Papalia, Antonella, additional, Papavasileiou, Apostolos, additional, Payen, Marie-Christine, additional, Pontali, Emanuele, additional, Robalo Cordeiro, Carlos, additional, Saderi, Laura, additional, Sadutshang, Tsetan Dorji, additional, Sanukevich, Tatsiana, additional, Solodovnikova, Varvara, additional, Spanevello, Antonio, additional, Topgyal, Sonam, additional, Toscanini, Federica, additional, Tramontana, Adrian R., additional, Farokh Udwadia, Zarir, additional, Viggiani, Pietro, additional, White, Veronica, additional, Zumla, Alimuddin, additional, and Migliori, Giovanni Battista, additional
- Published
- 2017
- Full Text
- View/download PDF
11. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
- Author
-
Tiberi, Simon, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Alarcon Guizado, Valentina, De Lorenzo, Saverio, Roby Arias, Aurora Jazmín, Scardigli, Anna, Akkerman, Onno O.W., Sotgiu, Giovanni, Aleksa, Alena, Artsukevich, Janina, Auchynka, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, D'Ambrosio, Lia, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Payen, Marie-Christine, Piana, Andrea, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Centis, Rosella, Migliori, Giovanni Battista, Arbex, Marcos Abdo, Alarcon Arrascue, Edith, Alffenaar, Jan Willem, Caminero, José Antonio, Gaga, Mina, Tiberi, Simon, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Alarcon Guizado, Valentina, De Lorenzo, Saverio, Roby Arias, Aurora Jazmín, Scardigli, Anna, Akkerman, Onno O.W., Sotgiu, Giovanni, Aleksa, Alena, Artsukevich, Janina, Auchynka, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, D'Ambrosio, Lia, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Payen, Marie-Christine, Piana, Andrea, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Centis, Rosella, Migliori, Giovanni Battista, Arbex, Marcos Abdo, Alarcon Arrascue, Edith, Alffenaar, Jan Willem, Caminero, José Antonio, and Gaga, Mina
- Abstract
No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanate versus meropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60-428) versus 85 (49-156) days, respectively. Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only. Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2016
12. Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB
- Author
-
Tiberi, Simon, De Lorenzo, Saverio, Gaga, Mina, Gualano, Gina, Roby Arias, Aurora Jazmín, Scardigli, Anna, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Akkerman, Onno O.W., Payen, Marie-Christine, Alarcon Arrascue, Edith, Aleska, Alena, Avchinko, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Sotgiu, Giovanni, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Migliori, Giovanni Battista, D'Ambrosio, Lia, Alarcon Guizado, Valentina, Alffenaar, Jan Willem, Arbex, Marcos Abdo, Caminero, José Antonio, Centis, Rosella, Tiberi, Simon, De Lorenzo, Saverio, Gaga, Mina, Gualano, Gina, Roby Arias, Aurora Jazmín, Scardigli, Anna, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Akkerman, Onno O.W., Payen, Marie-Christine, Alarcon Arrascue, Edith, Aleska, Alena, Avchinko, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Sotgiu, Giovanni, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Migliori, Giovanni Battista, D'Ambrosio, Lia, Alarcon Guizado, Valentina, Alffenaar, Jan Willem, Arbex, Marcos Abdo, Caminero, José Antonio, and Centis, Rosella
- Abstract
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6-9) versus 5 (4-6)). Patients were treated with a meropenem/clavulanate-containing regimen for a median (IQR) of 85 (49-156) days. No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/clavulanate (four of them then restarting treatment). The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/clavulanate could be active in treating MDR- and XDR-TB cases., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2016
13. Multicenter evaluation of xpert MTB/RIF ultra tests reporting detection of "Trace" of Mycobacterium tuberculosis DNA.
- Author
-
Mazzola, Ester, Monte, Paola, Piersimoni, Claudio, Giudice, Annalisa, Camaggi, Anna, Pedrotti, Cristina, Gurrieri, Francesca, Russo, Cristina, Farina, Claudio, Lombardi, Alessandra, Viggiani, Pietro, Cenci, Elio, Nisticò, Salvatore, Rognoni, Vanina, Sala, Eugenio, Cichero, Paola, Frizzera, Eliana, Monzillo, Vincenzina, Morini, Fulvia, and Scarparo, Claudio
- Published
- 2021
- Full Text
- View/download PDF
14. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis
- Author
-
Payen, Marie-Christine, primary, Tiberi, Simon, additional, Sotgiu, Giovanni Sotgiu, additional, D'ambrosio, Lia, additional, Centis, Rosella, additional, Abdo Arbex, Marcos, additional, Alarcon Arrascue, Edith, additional, Alffenaar, Jan Willem, additional, Caminero, Jose A., additional, Gaga, Mina, additional, Gualano, Gina, additional, Skrahina, Alena, additional, Solovic, Yvan, additional, Sulis, Giogia, additional, Tadolini, Marina, additional, Alarcon Guizado, Valentina, additional, De Lorenzo, Saviero, additional, Arias, Aurora, additional, Scardigli, Anna, additional, Akkerman, Onno W., additional, Aleksa, Alena, additional, Artsukevich, Janina, additional, Avchinko, Vera, additional, Bonini, Eduardo Henrique, additional, Chong Marin, Felix Antonio, additional, Collahuazo Lopez, Lorena, additional, de Vries, Gerard, additional, Dore, Simone, additional, Kunst, Heinke, additional, Matteelli, Alberto, additional, Moschos, Charalampos, additional, Palmieri, Fabrizio, additional, Papavasileiou, Apostolos, additional, Piana, Andrea, additional, Spanevello, Antonio, additional, Vargas Vasquez, Dante, additional, Viggiani, Pietro, additional, White, Veronica, additional, Zumla, Alimuddin, additional, and Migliori, Giovanni Battista, additional
- Published
- 2016
- Full Text
- View/download PDF
15. Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis
- Author
-
Tiberi, Simon, primary, Sotgiu, Giovanni, additional, D'Ambrosio, Lia, additional, Centis, Rosella, additional, Arbex, Marcos Abdo, additional, Alarcon Arrascue, Edith, additional, Alffenaar, Jan Willem, additional, Caminero, Jose A., additional, Gaga, Mina, additional, Gualano, Gina, additional, Skrahina, Alena, additional, Solovic, Ivan, additional, Sulis, Giorgia, additional, Tadolini, Marina, additional, Guizado, Valentina Alarcon, additional, De Lorenzo, Saverio, additional, Arias, Aurora Jazmin Roby, additional, Scardigli, Anna, additional, Akkerman, Onno W., additional, Aleksa, Alena, additional, Artsukevich, Janina, additional, Bonini, Eduardo Henrique, additional, Marin, Felix Antonio Chong, additional, Lopez, Lorena Collahuazo, additional, de Vries, Gerard, additional, Dore, Simone, additional, Kunst, Heinke, additional, Matteelli, Alberto, additional, Moschos, Charalampos, additional, Palmieri, Fabrizio, additional, Papavasileiou, Apostolos, additional, Payen, Marie-Christine, additional, Piana, Andrea, additional, Spanevello, Antonio, additional, Vasquez, Dante Vargas, additional, Viggiani, Pietro, additional, White, Veronica, additional, Zumla, Alimuddin, additional, and Migliori, Giovanni Battista, additional
- Published
- 2016
- Full Text
- View/download PDF
16. Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
- Author
-
Tiberi, Simon, primary, Sotgiu, Giovanni, additional, D'Ambrosio, Lia, additional, Centis, Rosella, additional, Abdo Arbex, Marcos, additional, Alarcon Arrascue, Edith, additional, Alffenaar, Jan Willem, additional, Caminero, Jose A., additional, Gaga, Mina, additional, Gualano, Gina, additional, Skrahina, Alena, additional, Solovic, Ivan, additional, Sulis, Giorgia, additional, Tadolini, Marina, additional, Alarcon Guizado, Valentina, additional, De Lorenzo, Saverio, additional, Roby Arias, Aurora Jazmín, additional, Scardigli, Anna, additional, Akkerman, Onno W., additional, Aleksa, Alena, additional, Artsukevich, Janina, additional, Auchynka, Vera, additional, Bonini, Eduardo Henrique, additional, Chong Marín, Félix Antonio, additional, Collahuazo López, Lorena, additional, de Vries, Gerard, additional, Dore, Simone, additional, Kunst, Heinke, additional, Matteelli, Alberto, additional, Moschos, Charalampos, additional, Palmieri, Fabrizio, additional, Papavasileiou, Apostolos, additional, Payen, Marie-Christine, additional, Piana, Andrea, additional, Spanevello, Antonio, additional, Vargas Vasquez, Dante, additional, Viggiani, Pietro, additional, White, Veronica, additional, Zumla, Alimuddin, additional, and Migliori, Giovanni Battista, additional
- Published
- 2016
- Full Text
- View/download PDF
17. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
- Author
-
Tiberi, Simon, primary, Payen, Marie-Christine, additional, Sotgiu, Giovanni, additional, D'Ambrosio, Lia, additional, Alarcon Guizado, Valentina, additional, Alffenaar, Jan Willem, additional, Abdo Arbex, Marcos, additional, Caminero, Jose A., additional, Centis, Rosella, additional, De Lorenzo, Saverio, additional, Gaga, Mina, additional, Gualano, Gina, additional, Roby Arias, Aurora Jazmín, additional, Scardigli, Anna, additional, Skrahina, Alena, additional, Solovic, Ivan, additional, Sulis, Giorgia, additional, Tadolini, Marina, additional, Akkerman, Onno W., additional, Alarcon Arrascue, Edith, additional, Aleska, Alena, additional, Avchinko, Vera, additional, Bonini, Eduardo Henrique, additional, Chong Marín, Félix Antonio, additional, Collahuazo López, Lorena, additional, de Vries, Gerard, additional, Dore, Simone, additional, Kunst, Heinke, additional, Matteelli, Alberto, additional, Moschos, Charalampos, additional, Palmieri, Fabrizio, additional, Papavasileiou, Apostolos, additional, Spanevello, Antonio, additional, Vargas Vasquez, Dante, additional, Viggiani, Pietro, additional, White, Veronica, additional, Zumla, Alimuddin, additional, and Migliori, Giovanni Battista, additional
- Published
- 2016
- Full Text
- View/download PDF
18. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
- Author
-
Tiberi, Simon, primary, D'Ambrosio, Lia, additional, De Lorenzo, Saverio, additional, Viggiani, Pietro, additional, Centis, Rosella, additional, Sotgiu, Giovanni, additional, Alffenaar, Jan Wilem C., additional, and Migliori, Giovanni Battista, additional
- Published
- 2015
- Full Text
- View/download PDF
19. Tuberculosis elimination, patients' lives and rational use of new drugs: revisited
- Author
-
Tiberi, Simon, primary, D'Ambrosio, Lia, additional, De Lorenzo, Saverio, additional, Viggiani, Pietro, additional, Centis, Rosella, additional, and Migliori, Giovanni Battista, additional
- Published
- 2015
- Full Text
- View/download PDF
20. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
- Author
-
Fabrizio Palmieri, Aurora Jazmín Roby Arias, Alena Skrahina, Gina Gualano, Giovanni Sotgiu, Dante Vargas Vasquez, Eduardo Henrique Bonini, Marina Tadolini, Gerard de Vries, Saverio De Lorenzo, Jose A. Caminero, Pietro Viggiani, Marcos Abdo Arbex, Valentina Alarcon Guizado, Apostolos Papavasileiou, Lorena Collahuazo López, Simon Tiberi, Simone Dore, Andrea Piana, Anna Scardigli, Vera Auchynka, Marie-Christine Payen, Antonio Spanevello, Felix Antonio Chong Marin, Alena Aleksa, Edith Alarcon Arrascue, Janina Artsukevich, Heinke Kunst, Alberto Matteelli, Onno W. Akkerman, Giorgia Sulis, Alimuddin Zumla, Giovanni Battista Migliori, Lia D'Ambrosio, Ivan Solovic, Jan-Willem C. Alffenaar, Mina Gaga, Charalampos Moschos, Veronica White, Rosella Centis, Tiberi, Simon, Sotgiu, Giovanni, D'Ambrosio, Lia, Centis, Rosella, Arbex, Marcos Abdo, Arrascue, Edith Alarcon, Alffenaar, Jan Willem, Caminero, Jose A., Gaga, Mina, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Guizado, Valentina Alarcon, De Lorenzo, Saverio, Arias, Aurora Jazmín Roby, Scardigli, Anna, Akkerman, Onno W., Aleksa, Alena, Artsukevich, Janina, Auchynka, Vera, Bonini, Eduardo Henrique, Marín, Félix Antonio Chong, López, Lorena Collahuazo, De Vries, Gerard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Moschos, Charalampo, Palmieri, Fabrizio, Papavasileiou, Apostolo, Payen, Marie-Christine, Piana, Andrea, Spanevello, Antonio, Vasquez, Dante Varga, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Migliori, Giovanni Battista, and Microbes in Health and Disease (MHD)
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Imipenem ,medicine.drug_class ,DELAMANID ,Antibiotics ,Drug resistance ,MULTIDRUG-RESISTANT ,Meropenem ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,COMPASSIONATE USE ,polycyclic compounds ,Culture conversion ,MEROPENEM-CLAVULANATE ,Medicine ,030212 general & internal medicine ,business.industry ,Medicine (all) ,DRUG-RESISTANT TUBERCULOSIS ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,EFFICACY ,BEDAQUILINE ,Multiple drug resistance ,030228 respiratory system ,Tolerability ,TOLERABILITY ,MYCOBACTERIUM-TUBERCULOSIS ,Delamanid ,business ,LINEZOLID SAFETY ,medicine.drug - Abstract
No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanateversusmeropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanateversusmeropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases.84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8versus8) but more fluoroquinolone resistance (79.0%versus48.9%, pversus49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60–428)versus85 (49–156) days, respectively.Statistically significant differences were observed on sputum smear and culture conversion rates (79.7%versus94.8%, p=0.02 and 71.9%versus94.8%, pversus77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only.Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients.
- Published
- 2016
21. Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB
- Author
-
Fabrizio Palmieri, Jose A. Caminero, Marcos Abdo Arbex, Onno W. Akkerman, Pietro Viggiani, Eduardo Henrique Bonini, Giorgia Sulis, Gina Gualano, Charalampos Moschos, Veronica White, Simone Dore, Alimuddin Zumla, Heinke Kunst, Aurora Jazmín Roby Arias, Alena Skrahina, Giovanni Battista Migliori, Lorena Collahuazo López, Lia D'Ambrosio, Gerard de Vries, Alberto Matteelli, Rosella Centis, Valentina Alarcon Guizado, Anna Scardigli, Jan-Willem C. Alffenaar, Mina Gaga, Felix Antonio Chong Marin, Antonio Spanevello, Ivan Solovic, Marina Tadolini, Marie-Christine Payen, Edith Alarcon Arrascue, Saverio De Lorenzo, Apostolos Papavasileiou, Vera Avchinko, Giovanni Sotgiu, Simon Tiberi, Dante Vargas Vasquez, Alena Aleska, Tiberi, Simon, Payen, Marie Christine, Sotgiu, Giovanni, D'Ambrosio, Lia, Guizado, Valentina Alarcon, Alffenaar, Jan Willem, Arbex, Marcos Abdo, Caminero, Jose A., Centis, Rosella, De Lorenzo, Saverio, Gaga, Mina, Gualano, Gina, Arias, Aurora Jazmín Roby, Scardigli, Anna, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Akkerman, Onno W., Arrascue, Edith Alarcon, Aleska, Alena, Avchinko, Vera, Bonini, Eduardo Henrique, Marín, Félix Antonio Chong, López, Lorena Collahuazo, De Vries, Gerard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Moschos, Charalampo, Palmieri, Fabrizio, Papavasileiou, Apostolo, Spanevello, Antonio, Vasquez, Dante Varga, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Migliori, Giovanni Battista, and Microbes in Health and Disease (MHD)
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,DELAMANID ,Drug resistance ,MULTIDRUG-RESISTANT ,Meropenem ,03 medical and health sciences ,Antitubercular Agent ,0302 clinical medicine ,Interquartile range ,Retrospective Studie ,Internal medicine ,COMPASSIONATE USE ,Tuberculosis, Multidrug-Resistant ,medicine ,Culture conversion ,MEROPENEM-CLAVULANATE ,030212 general & internal medicine ,Thienamycin ,Adverse effect ,METAANALYSIS ,Clavulanic Acid ,business.industry ,Medicine (all) ,DRUG-RESISTANT TUBERCULOSIS ,EFFICACY ,BEDAQUILINE ,Surgery ,Multiple drug resistance ,Regimen ,Treatment Outcome ,030228 respiratory system ,Tolerability ,Extensively Drug-Resistant Tuberculosi ,TOLERABILITY ,Female ,business ,LINEZOLID SAFETY ,medicine.drug ,Human - Abstract
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases.Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, pversus 5 (4–6)). Patients were treated with a meropenem/clavulanate-containing regimen for a median (IQR) of 85 (49–156) days.No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/clavulanate (four of them then restarting treatment).The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/clavulanate could be active in treating MDR- and XDR-TB cases.
- Published
- 2016
22. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis
- Author
-
Valentina Alarcon Guizado, Giovanni Sotgiu, Alberto Matteelli, Veronica White, Eduardo Henrique Bonini, Marina Tadolini, Mina Gaga, Saverio De Lorenzo, Fabrizio Palmieri, Lorena Collahuazo López, Aurora Jazmín Roby Arias, Rosella Centis, Ivan Solovic, Anna Scardigli, Edith Alarcon Arrascue, Alena Skrahina, Antonio Spanevello, Marie-Christine Payen, Heinke Kunst, Janina Artsukevich, Vera Avchinko, Apostolos Papavasileiou, Giorgia Sulis, Gerard de Vries, Pietro Viggiani, Charalampos Moschos, Lia D'Ambrosio, Onno W. Akkerman, Jan-Willem C. Alffenaar, Simone Dore, Dante Vargas Vasquez, Simon Tiberi, Alimuddin Zumla, Giovanni Battista Migliori, Andrea Piana, Alena Aleksa, Felix Antonio Chong Marin, Jose A. Caminero, Marcos Abdo Arbex, Gina Gualano, Microbes in Health and Disease (MHD), Tiberi, Simon, Sotgiu, Giovanni, D'Ambrosio, Lia, Centis, Rosella, Arbex, Marcos Abdo, Alarcon Arrascue, Edith, Alffenaar, Jan Willem, Caminero, Jose A., Gaga, Mina, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Alarcon Guizado, Valentina, De Lorenzo, Saverio, Roby Arias, Aurora Jazmín, Scardigli, Anna, Akkerman, Onno W., Aleksa, Alena, Artsukevich, Janina, Avchinko, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gerard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Moschos, Charalampo, Palmieri, Fabrizio, Papavasileiou, Apostolo, Payen, Marie Christine, Piana, Andrea, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, and Migliori, Giovanni Battista
- Subjects
Infectious Diseases ,Microbiology (medical) ,Medicine (all) ,Extensively Drug-Resistant Tuberculosis ,Treatment outcome ,Antitubercular Agents ,Microbiology ,Antitubercular Agent ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Medicine ,030212 general & internal medicine ,Clavulanic Acid ,METAANALYSIS ,OUTCOMES ,business.industry ,Imipenem ,Treatment Outcome ,TB ,030228 respiratory system ,Extensively Drug-Resistant Tuberculosi ,Drug Therapy, Combination ,business ,Humanities ,Human - Abstract
Simon Tiberi, Giovanni Sotgiu, Lia D’Ambrosio, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Jan Willem Alffenaar, Jose A. Caminero, Mina Gaga, Gina Gualano, Alena Skrahina, Ivan Solovic, Giorgia Sulis, Marina Tadolini, Valentina Alarcon Guizado, Saverio De Lorenzo, Aurora Jazmin Roby Arias, Anna Scardigli, Onno W. Akkerman, Alena Aleksa, Janina Artsukevich, Vera Avchinko, Eduardo Henrique Bonini, Felix Antonio Chong Marin, Lorena Collahuazo Lopez, Gerard de Vries, Simone Dore, Heinke Kunst, Alberto Matteelli, Charalampos Moschos, Fabrizio Palmieri, Apostolos Papavasileiou, Marie-Christine Payen, Andrea Piana, Antonio Spanevello, Dante Vargas Vasquez, Pietro Viggiani, Veronica White, Alimuddin Zumla and Giovanni Battista Migliori
- Published
- 2016
23. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
- Author
-
Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, and Migliori GB
- Subjects
- Adult, Cohort Studies, Comparative Effectiveness Research, Drug Resistance, Bacterial, Female, Humans, Male, Meropenem, Middle Aged, Sputum metabolism, Time Factors, Treatment Outcome, Antitubercular Agents administration & dosage, Clavulanic Acid administration & dosage, Extensively Drug-Resistant Tuberculosis drug therapy, Imipenem administration & dosage, Thienamycins administration & dosage, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanate versus meropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases.84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60-428) versus 85 (49-156) days, respectively.Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only.Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients., (Copyright ©ERS 2016.)
- Published
- 2016
- Full Text
- View/download PDF
24. Tuberculosis elimination, patients' lives and rational use of new drugs: revisited.
- Author
-
Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, and Migliori GB
- Subjects
- Adult, Disease Eradication, Extensively Drug-Resistant Tuberculosis prevention & control, Humans, Male, Retreatment, Salvage Therapy, Treatment Failure, Tuberculosis drug therapy, Tuberculosis prevention & control, Tuberculosis, Pulmonary prevention & control, World Health Organization, Antitubercular Agents therapeutic use, Drug Discovery, Extensively Drug-Resistant Tuberculosis drug therapy, Tuberculosis, Pulmonary drug therapy
- Published
- 2016
- Full Text
- View/download PDF
25. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.
- Author
-
Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, Alffenaar JW, and Migliori GB
- Subjects
- Adult, Drug Therapy, Combination, Ertapenem, Female, Humans, Male, Middle Aged, Retrospective Studies, Young Adult, Anti-Bacterial Agents therapeutic use, Antitubercular Agents therapeutic use, Extensively Drug-Resistant Tuberculosis drug therapy, Tuberculosis, Multidrug-Resistant drug therapy, beta-Lactams therapeutic use
- Published
- 2016
- Full Text
- View/download PDF
26. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
- Author
-
Tiberi S, De Lorenzo S, Centis R, Viggiani P, D'Ambrosio L, and Migliori GB
- Subjects
- Adult, Aged, Compassionate Use Trials, Female, Humans, Male, Treatment Outcome, Tuberculosis, Multidrug-Resistant drug therapy, Antitubercular Agents therapeutic use, Diarylquinolines therapeutic use, Extensively Drug-Resistant Tuberculosis drug therapy
- Published
- 2014
- Full Text
- View/download PDF
27. AmBisome treatment of pulmonary aspergillosis in a patient with tuberculosis.
- Author
-
Viggiani P and Besozzi G
- Subjects
- Aged, Humans, Male, Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Aspergillosis complications, Aspergillosis drug therapy, Lung Diseases, Fungal complications, Lung Diseases, Fungal drug therapy, Tuberculosis, Pulmonary complications
- Abstract
This case report describes the history of a patient with pulmonary tuberculosis. As part of the diagnostic work-up a transthoracic biopsy was performed which resulted in a lung collapse. After one month of standard therapy for tuberculosis, the patient was admitted to our hospital for a clinical and surgical re-evaluation. Microbiological examination showed the presence of Aspergillus niger and Pseudomonas aeruginosa. Treatment with AmBisome, ciprofloxacin and imipenem was started: the patient responded well with good clinical improvement. After 5 months of anti-tuberculous therapy, culture of pleural fluid was negative; the right lung remained collapsed but sterilization of the pleura will allow future surgery.
- Published
- 2006
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.